DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2044
INDEX
Lymphoma(s), 1755
drugs for, 1668t–1670t
Lymphomatoid papulosis,
methotrexate for, 1820
Lypressin, 709t
Lysergic acid diethylamide (LSD), 349
Lysine conopressin, 709t
Lysinuric protein intolerance, 102t
LYSTEDA (tranexamic acid), 867–868
M
MAALOX QUICK DISSOLVE, 1316t
MAALOX TC, 1316t
Macroglobulinemia, primary, drugs
for, 1668t–1670t
Macrolides, 1327–1328, 1563
absorption of, 1531
antibacterial activity of, 1529–1530
distribution of, 1531
drug interactions with, 1534
elimination of, 1531–1532
polymorphisms and response to,
159t
resistance to, 1530–1531
and statins, interactions, 896
therapeutic uses of, 1532–1533
untoward effects of, 1533–1534
Macrophage colony-stimulating factor
(M-CSF), 1070t
MACUGEN (pegaptanib), 1794
Macula densa, 673
and renin release, 722, 723f
Maculopathy, toxic, niacin-associated,
900
Mafenide, pharmacological properties
of, 1466–1467
Magnesium
antiarrhythmic use of, 824t, 842
and bowel function, 1330t
electrophysiological actions
of, 829t
for torsades de pointes, 842
Magnesium sulfate
for asthma, 1046
for pre-eclampsia, 1847
for prevention of preterm labor,
1848
Ma huang, 3
Maintenance dose, 35–36
Maintenance immunotherapy,
1007
Major depression, 421
Major facilitator superfamily, 97
MAL. See Methylaminolevulinate
Malabsorption, and vitamin K, 874
Malaria. See also Antimalarial agents
biology of, 1383–1385
clinical manifestations of, 1385
prophylaxis, 1411–1415
Malathion, 243
as insecticide, 243
mechanism of action of, 1819
parathion and, 239
structure of, 1819
Male contraception, 1204
Male infertility, 1124
Malignancy
calcineurin inhibitors and,
1822
chemoprevention, 1811
Malignant hyperthermia,
neuromuscular blocking
agents and, 268
Malignant hyperthermia antidote, 86t
Malignant melanoma, drugs for,
1668t–1670t
Mammalian target of rapamycin
(mTOR), 1743. See also
mTOR inhibitors
Mammary glands. See Breast
MANDOL (cefamandole), 1494t
Mania
anticonvulsants for, 444–445
drugs for, 420–423
lithium for, 445–447
novel treatments of, 451
treatment of, 444–451
Mannitol, 681
pharmacology of, 681t
structure of, 681t
MAOIs. See Monoamine oxidase
inhibitors (MAOIs)
Maprotiline
disposition of, 409t
potencies
at human transporters for
monamine neurotransmitters,
406t
at neurotransmitter receptors,
410t
side effects of, 401t
Maraviroc, 1656–1657
pharmacokinetics of, 1859t
MAREZINE (cyclizine hydrochloride;
cyclizine lactate), 921t
Margin of safety, 74
Marijuana
abuse of, 663–664
hypoglycemia and, 1248t
Marketing, of drugs, 12–13
Mast cells
dermal, 1804
neuromuscular blocking agents and,
262–263
proliferation of, histamine and, 915
Mastocytosis, systemic, NSAIDs for,
971
MATEs. See Multidrug and toxin
extrusion family (MATEs)
MAVIK (trandolapril), 733, 797
MAXIFLOR (diflorasone diacetate),
1225t
Maximum Recommended Therapeutic
Dose database, 1813
MAXIPME (cefepime), 1494t, 1496t
MDR1 gene, 89
MDS. See Myelodysplastic syndrome
(MDS)
Mebendazole, hypoglycemia and,
1248t
Mecamylamine, 272
structure of, 273f
Mechanism of action, 51–65
Mechlorethamine, 1668t–1670t, 1683
Mechlorethamine hydrochloride
adverse effects and side effects of,
1821
in dermatology, 1821
mechanism of action of, 1820t
Meclizine, 921t, 924
therapeutic uses of, 923
Meclofenamate sodium, 989
adverse effects and side effects of,
989
compared to aspirin, 968t
COX isoform selectivity, 962f
dosage and administration of, 968t
pharmacokinetics of, 968t
pharmacology of, 962f
Median effective dose (ED 50
),
73, 74f
Median lethal dose (LD 50
), 73, 74f
animal testing of, 78
Mediator antagonists, 1052–1054
Medical addict, 654
Medical errors, 1883
“Medical imperialism,” 13
Medication errors, reduction of, 80–81
Medication errors, “Swiss cheese”
model of, 81t
Medication seeking, 1882–1883
Medroxyprogesterone, in cancer
chemotherapy, 1756
Medroxyprogesterone acetate (MPA),
1668t–1670t, 1766